This is one of the quieter shifts that comes with GLP-1 medications, and it sneaks up on a lot of people
#PharmaInsights #Retatrutide #Obesity #GLP1 #GIP #Glucagon #ObesityMedicine #ClinicalResearch #MedicalEducation #EvidenceBasedMedicine #PharmaceuticalMarketing To view or add a comment, sign in Recent clinical trial data on aleniglipron underscores three critical developments in obesity pharmacotherapy
GH-secreting tumors are typically recognized in the fifth decade of life
Semaglutide is registered with the FDA while Semaglutide sodium is not, we do not promote the use of the sodium salt
Among female subjects under 40 taking GLP-1 M, the simultaneous use of non-steroidal anti-inflammatory drugs (NSAIDs) was associated with a greater reduction in HbA1C (0.82 1.72% vs 0.28 1.70%, p = 0.008)
Some people are not candidates, including pregnancy and breastfeeding scenarios, which is why Safety considerations / medical supervision matters